VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 24 2025
0mins
Source: Globenewswire
VivoSim Labs Emerges from Stealth Mode: VivoSim Labs, Inc. has launched its innovative drug discovery methodologies that utilize non-animal testing models for liver and intestinal toxicology, coinciding with the FDA's initiative to phase out animal testing in favor of more predictive and ethical alternatives.
Impact on Drug Development: The company's NAMkind™ models aim to significantly reduce clinical trial failures and development costs by providing superior predictions of drug toxicity, potentially transforming the pharmaceutical industry and improving patient outcomes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
